Targeting the IL-6 receptor with the monoclonal antibody tocilizumab significantly improves quality of life in patients with rheumatoid arthritis

被引：0
|
作者：
Smolen, J. [1 ,2 ]
Atkins, C. [3 ]
Rovensky, J. [4 ]
Ramos-Remus, C. [5 ]
Lucero, M. [6 ]
Woodworth, T. [7 ]
Alten, R. [8 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Hietzing Hosp, Vienna, Austria
[3] Vancouver Isl Hlth Author Grp, Div Rheumatol & PreCuro Clin Res, Vancouver, BC, Canada
[4] Natl Inst Rheumat Dis, Piestany, Slovakia
[5] Res Unit Chron Dis, Guadalajara, Mexico
[6] Hoffmann La Roche AG, Basel, Switzerland
[7] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[8] Univ Med, Schlosspk Clin, D-13353 Berlin, Germany
来源：
JOURNAL OF RHEUMATOLOGY | 2008年 / 35卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1181 / 1182
页数：2
相关论文
共 50 条
  • [1] Tocilizumab, a novel monoclonal antibody targeting il-6 signalling, significantly improves quality of life in patients with rheumatoid arthritis
    Allen, R.
    Ramos-Remus, C.
    Rovensky, J.
    Lucero, M.
    Woodworth, T.
    Smolens, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 428 - 428
  • [2] Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis
    Smolen, J.
    Beaulieu, A.
    Rubbert-Roth, A.
    Alecock, E.
    Alten, R.
    Woodworth, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 87 - 88
  • [3] The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
    Diaz-Torne, Cesar
    Ortiz, Maria A.
    Moya, Patricia
    Victoria Hernandez, M.
    Reina, Delia
    Castellvi, Ivan
    Jose De Agustin, Juan
    De La Fuente, Diana
    Corominas, Hector
    Sanmarti, Raimon
    De Llobet Zubiaga, Josep Maria
    Vidal, Silvia
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    [J]. FORMULARY, 2008, 43 (08) : 272 - 279
  • [5] Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs
    Gomez-Reino, J. J.
    Nair, B.
    Fairfax, M. J.
    Pavelka, K.
    Alecock, E.
    Woodworth, T.
    Genovese, M.
    [J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1216 - 1216
  • [6] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
    Ali Berkant Avci
    Eugen Feist
    Gerd Rüdiger Burmester
    [J]. BioDrugs, 2018, 32 : 531 - 546
  • [7] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Ruediger
    [J]. BIODRUGS, 2018, 32 (06) : 531 - 546
  • [8] The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab
    Diaz-Torne, Cesar
    Angels Ortiz, Maria dels
    Moya, Patricia
    Victoria Hernandez, Maria
    Reina, Delia
    Castelivi, Ivan
    Jose De Agustin, Juan
    de la Fuente, Diana
    Corominas, Hector
    Sanmarti, Raimon
    Zamora, Carlos
    Canto, Elisabet
    Vidal, Silvia
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 47 (06) : 757 - 764
  • [9] Quality of life and functional improvements with the IL-6 receptor inhibitor tocilizumab in patients with active rheumatoid arthritis despite DMARD therapy: The toward study
    Gomez-Reino, Juan J.
    Fairfax, M. J.
    Pavelka, K.
    Alecock, E.
    Woodworth, T.
    Laughton, J.
    Eves, D.
    Genovese, M. C.
    [J]. RHEUMATOLOGY, 2008, 47 : II49 - II49
  • [10] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
    Ali Berkant Avci
    Eugen Feist
    Gerd R. Burmester
    [J]. BioDrugs, 2024, 38 : 61 - 71
12345